IL17A and cancer: Therefore, we speculate that the tumor tissue of high-risk patients may activate the IL-17 signaling pathway by up-regulating the expression of the NTRK2 gene, so as to inhibit the activity of CD56bright natural killer cells to reduce its abundance of tumor infiltration, thus preventing its inhibition and the elimination of malignant tumor cells.